Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

Relief for baby and child care at the UFS with donation from Fuchs Foundation
2007-11-17

 

At the launch of the Beds of Hope campaign were, from the left: Dr Riaan Els, Chief Executive Officer of the Carl en Emily Fuchs Foundation, Prof. André Venter (Head of the Department of Paediatrics and Child Care), Ms Corné Booyens (National Grants Manager at the Carl en Emily Fuchs Foundation), Dr Nick van Zyl (Clinical Head at Universitas Hospital), and Prof. Niel Viljoen (Chief Director: Operations).
Photo: Leonie Bolleurs

Relief for baby and child care at the UFS with donation from Fuchs Foundation

The Department of Paediatrics and Child Health at the University of the Free State (UFS) has received relief for their need of specialised healthcare for babies and children with a donation of R1,5 million from the Carl and Emily Fuchs Foundation.

As a result of this, the Beds of Hope campaign was launched today on the Main Campus in Bloemfontein. With the campaign, the department wants to address the serious need for specialised healthcare for babies and children in the central regions of South Africa.

The department is one of four out of 19 children hospitals in South Africa to receive such a donation. .

“We take care of babies and children in the Universitas and Pelonomi Hospitals in Bloemfontein who have a serious need for specialised healthcare. We are, however, the only supplier of this kind of care in the Free State, North West, Eastern Cape and Lesotho and are responsible for the specialised healthcare of more than 100 000 children. Many of our equipment are outdated and must be urgently repaired or replaced,” said Prof. André Venter, Head of the Department of Paediatrics and Child Care at the UFS.

“Because we are concerned about our patients, the department launched the Beds of Hope campaign with the help of the donation we received from the Fuchs Foundation. With the campaign, we aim to raise some R15 million in the space of two years to purchase beds and specialised equipment for the intensive care and high care units for both hospitals,” said Prof. Venter.
According to Prof. Venter, this includes babies and children with needs for specialised healthcare in the fields of intensive care, oncology, cardiology, neurology, endocrinology, gastro-enterology, neonatology and infectious diseases.

“About ten children are currently not receiving the care they need due to the lack of beds in the intensive care unit. Much more neonates can annually receive critical care if we can supply adequate facilities,” said Prof. Venter.

The other hospitals that are also supported by the Fuchs Foundation’s donation are: Healing Jozi Kids, Boikanyo Foundation and the Groote Schuur Hospital’s neonatal department.

The donation is the beginning of the first phase of the national Fuchs Healing Kids Project, which aims to improve the quality of paediatric care in South Africa.

The aim of this phase is to assist the hospitals to develop the systems and skills needed to collect more money. The research part of phase two and the building up of the hospitals’ children trust funds to be self self-supporting, will happen simultaneously. This phase will be launched early in 2008.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
16 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept